Kids playing Kids playing

ProAir HFA
inhaler features

*From date of manufacture, Not the same as expiration date. Patients should discard the inhaler when the dose counter reads zero or after the expiration date, whichever occurs first.

Short-Acting Beta2-Agonist* Characteristics Chart1-8

Expiration
ProAir® HFA Up to 24 months
Proventil® HFA Up to 24 months
Ventolin® HFA Up to 12 months after opening pouch
Xopenex® HFA Up to 24 months
Special Storage Requirements
ProAir® HFA No:
Store in any
position
Proventil® HFA No:
Store in any
position
Ventolin® HFA Yes:
Store with Mouthpiece Down
Xopenex® HFA No:
Store in any
position
Dose Counter
ProAir® HFA Yes
Proventil® HFA N/A
Ventolin® HFA Yes
Xopenex® HFA N/A
No Need To
Re-prime if Dropped
ProAir® HFA Yes
Proventil® HFA Yes
Ventolin® HFA No
Xopenex® HFA Yes
Non-use Time
Without Re-priming
ProAir® HFA 14 days
Proventil® HFA 14 days
Ventolin® HFA 14 days
Xopenex® HFA 3 days
Products Expiration Special Storage Requirements Dose
Counter
No Need To
Re-prime if Dropped
Non-use Time
Without Re-priming
ProAir® HFA Up to 24 months No:
Store in any
position
Yes Yes 14 days
Proventil® HFA Up to 24 months No:
Store in any
position
N/A Yes 14 days
Ventolin® HFA Up to 12 months after opening pouch Yes:
Store with Mouthpiece Down
Yes No 14 days
Xopenex® HFA Up to 24 months No:
Store in any
position
N/A Yes 3 days

Product characteristics listed are not all inclusive and cannot be used to infer product efficacy or safety.

The brands listed are registered trademarks of their respective owners.
Doesn’t have to be stored upright to guarantee dosing consistency.

Indications

ProAir HFA (albuterol sulfate) Inhalation Aerosol is indicated in patients ≥4 years of age for the treatment or prevention of bronchospasm with reversible obstructive airway disease and in patients ≥4 years of age for the prevention of exercise-induced bronchospasm.

Important Safety Information

  • Contraindications: ProAir HFA is contraindicated in patients with hypersensitivity to albuterol
  • Paradoxical Bronchospasm: ProAir HFA can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir HFA and institute alternative therapy if paradoxical bronchospasm occurs
  • Deterioration of Asthma: Need for more doses of ProAir HFA than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment, such as possible need for anti-inflammatory treatment, e.g., corticosteroids
  • Use of Anti-Inflammatory Agents: ProAir HFA alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids
  • Cardiovascular Effects: ProAir HFA, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued. ProAir HFA, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension
  • Do Not Exceed Recommended Dose: Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma
  • Immediate Hypersensitivity Reactions may occur after administration of albuterol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema
  • Coexisting Conditions: ProAir HFA, like all sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines.
  • Hypokalemia: As with other beta-agonists, ProAir HFA may produce significant hypokalemia in some patients. The decrease is usually transient, not requiring supplementation
  • Most common adverse reactions (≥3.0% and >placebo): are headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis
  • Drug Interactions: Other short-acting sympathomimetic bronchodilators should not be used concomitantly with ProAir HFA
    • Beta-Blockers: Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as ProAir HFA, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers
    • Diuretics: Caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics (such as loop or thiazide diuretics). Consider monitoring potassium levels
    • Digoxin: Carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and ProAir HFA
    • Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: ProAir HFA should be administered with extreme caution to patients being treated with these agents, or within 2 weeks of discontinuation of these agents, because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy

  • Please read the full Prescribing Information.

REFERENCES

1.ProAir HFA Prescribing Information. Parsippany, NJ: Teva Respiratory, LLC.

2.Data on File (Quality Control/Quality Assurance) West Chester, PA Teva Branded Pharmaceutical Products R&D, Inc.

3.Ventolin HFA Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; December 2014.

4.Proventil HFA Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; December 2014.

5.Xopenex HFA Prescribing Information. Marlborough, MA: Sunovion Pharmaceuticals Inc.; March 2015.